Autonomix reports pain reduction in pancreatic cancer patient treatment

Autonomix Medical announced 4-6 week preliminary positive results from the first five “lead-in” patients in the Company’s ongoing proof-of-concept human clinical trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain. Three patients were treated with femoral access and two were treated with brachial access. All patients treated with femoral access positively responded to treatment and patients treated with brachial access showed no improvement in their pain scores. 60% of patients responded with a mean of 6.67, or 83%, reduction of pain on the VAS pain scale (from baseline of 8.0 to 1.33) at 4-6 weeks post-procedure. 66% of responders reported a VAS pain score of 0 or 1 with a greater than 7-point reduction in pain score at 4-6 weeks post-procedure. 100% of the responder group had clinically meaningful pain relief at 4-6 weeks post-procedure. “We are encouraged by the significant, sustained pain reduction demonstrated from the lead-in patients in our ongoing first-in-human trial. These are very sick individuals, who up until this point primarily relied on opioids to help mitigate their pain, which our baseline data shows were not effective. Following our treatment, all the responders had a clinically meaningful mean reduction in pain from 8 to 1.33 on the VAS pain scale at 4-6 weeks post-procedure,” commented Brad Hauser, CEO. “While these data are preliminary, we are excited about our precision nerve-targeted technology and the potential it has to revolutionize electrophysiology therapies.”